Antihypertensive drugs use in Spain, 1985-1995;Uso de antihipertensivos en Espana, 1985-1995

Medicina Clinica

Volumn 110, Issue 7, 1998, Pages 247-253

  Prieto, Marta ^a   De Abajo, Francisco José ^a   Montero, Dolores ^a   Martín Serrano, Gloria ^a   Madurga, Mariano ^a   Palop, Ramón ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; NIFEDIPINE; RAUWOLFIA ALKALOID; THIAZIDE DIURETIC AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; BENZOTHIADIAZINE DERIVATIVE; DIURETIC AGENT;

ARTICLE; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; HUMAN; HYPERTENSION; PRESCRIPTION; SPAIN; COMPARATIVE STUDY; COST; ECONOMICS; EVALUATION; STATISTICS;

ADRENERGIC ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; CALCIUM CHANNEL BLOCKERS; COSTS AND COST ANALYSIS; DIURETICS; DRUG UTILIZATION; EVALUATION STUDIES; HUMANS; SODIUM CHLORIDE SYMPORTER INHIBITORS; SPAIN;

EID: 0032574064     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA 1996; 275: 1.571-1.576.
2. Ministerio de Sanidad y Consumo. Control de la hipertension arterial en Espana, 1996. Madrid: IDEPSA. 1996.
3. Collins R, Peto R, McMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
4. Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. JAMA 1996; 275: 1.577-1.580.
5. Ad hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105-115.
6. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS et al. The risk of myocardial infarction associated with antihyoertensive drug therapies. JAMA 1995, 274: 620-625.
7. Pabor M, Guralnik JM, Corte MC, Foley DJ, Carbonien P, Havlik RJ et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1 191-1.197.
8. Roca-Cusachs A, Rodicio JL. Antagonistas del calcio y su impacto sobre el riesgo coronario. Mod Clin (Barc) 1996; 107: 533-534
9. Capellà D, Porta M, Laporte JR. Utilization of antihypertensive drugs in certain European countries. Eur J Clin Pharmacol 1983; 25: 431-435.
10. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. Oslo: WHO CCDSM, 1996
11. Alonso MP, De Abajo FJ, Martinez J, Montero D, Martin-Serrano G, Madurga M. Evolución del consumo de antidepresivos en España. Impacto de los inhibidores selectives de la recaptaciõn de serotonina. Med Clin (Barc) 1997; 108: 161-166.
12. Capellà D. Descriptive tools and analysis, En: Dukes MNG, editor, Drug utilization studies-methods and uses. Copenhague: WHO Regional Publications, European series n.o 45, 1993.
13. Iñesta A. La presentación farmacéutica en el Sistema Nacional de Salud. Madrid: Escuela Nacional de Saridad, julio de 1996. Documento docente.
14. Olin BR, editor. Drug facts and comparisons. St. Louis: Facts and Comparisons, Inc., 1996.
15. Liga Española para la Lucha contra la Hipertension arterial. Situación actual de la detección, tratamiento y control de la hipertensión arterial en España. Madrid: Liga Espanola para la Lucha contra la Hipertensión arterial, 1995.
16. Banegas JR, Villar F, Pérez de Andrés C. Jiménez R, Gil E, Muñiz J et al Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años. Rev San Hig Pub 1993; 67: 419-445.
17. Silusson E, Magnusson E. Notkun Lyfia. 1989-1993. Heilbrigois-og: Trygginganálavao Uneytisin, 1993.
18. Norsk Medisinaldepot As. Legemiddelforbruket Novge, 1989-1993. Oslo: NMD, 1994.
19. Nordenstam I, Wennberg M, Kristoferson K. Svensk Läkemedels-Statistik, 1993. Estocolmo: Apoteksbolaget, 1994.
20. Guidelines for the treatment of mild hypertension: Memorandum from a WHO/ISH meeting Lancet 1983; 1: 457-458.
21. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The 1984 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, Arch Intern Med 1984; 144: 1.045-1.057
22. Fraser HS. Reserpine: a tragic victim of myths, marketing and fashionable prescribing. Clin Pharmacol Ther 1996; 60: 368-373.
23. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153: 154-183.
24. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WD. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995; 155: 829-837.
25. Siscovick DS, Raghunathan TE, Psaty BM. Koepsell TD, Wicklund KD, Lin X et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1.852-1857.
26. Badia X, Rovira J, Tresserras R, Trinxet C, Segu JL, Pardell H. El coste de la hipertensión arterial en España. Med Clin (Barc) 1992; 99: 769-773.
27. Hilleman DE. Cost-minim zation analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1993; 16: 88-102.
28. Johanesson M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy 1994; 28: 1-13.
29. Beto JA, Bausal VK. Quality of life in treatment of hypertension: a metaanalysis of clinical trials. Am J Hypertens 1992; 5: 125-133.
30. Bulpitt CJ, Fletcher AE Quality of life evaluation of antihypertensive drugs. Pharmacoeconomics 1992; 1: 95-102.
31. Furberg CD, Psaty AE, Meyer JV. Nifedipinedose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1.326-1.331.
32. Serna JL. Un fármaco en apuros. La FDA alerta sobre el uso de nifedipino de acción corta en la hipertension. El Mundo, 1 de febrero de 1996.
33. Beevers DG, Sleghl P. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? Br Med J 1996; 312: 1.143-1.145.
34. Pahor M, Guralnik JM, Furberg C Carbonien P, Havlik RJ. Risk of gastrointestinal hemorrhage with calcium antagonists in hypertensive persons over 67 years old Lancet 1996; 347: 1.061-1.065.
35. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
36. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolac, other NSAIDs, calcium antagonists and other antihypertensives. Arch Intern Med 1997. En prensa.